A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Active, not recruiting · Phase 3 · NCT03673501
Conditions: Gastrointestinal Stromal Tumors
At a glance
- Research payments reported, 2025
- $1.9M
- U.S. investigators named
- 13
- Sites paid
- 14
- Planned or actual enrollment
- 453
About the trial
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Tested
- Ripretinib (drug), Sunitinib (drug)
- Dates
- Started 2019-02-08; completion 2027-12
- Results posted
- Yes
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).
From ClinicalTrials.gov, last updated 2026-10-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Deciphera Pharmaceuticals Inc. reported $1.9M in research payments for this study in 2025 (189 payments).
Products named: Qinlock
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Mahesh Seetharam, MD, FACP Hematology & Oncology · Phoenix, AZ
- Arun S. Singh, M.D. Hematology & Oncology · Santa Monica, CA
- Hari A. Deshpande, MD Interventional Cardiology · New Haven, CT
- Steven Attia, DO Hematology & Oncology · Jacksonville, FL
- Mihaela Druta, M.D. Medical Oncology · Tampa, FL
- Jonathan C. Trent II, M.D., PH. D. Medical Oncology · Miami, FL
- Mohammed M. Milhem, MBBS Hematology & Oncology · Iowa City, IA
- Aparna Kalyan, MD Hematology & Oncology · Chicago, IL
- Ping Chi, M.D., PH.D. Medical Oncology · New York, NY
- Andreas Kaubisch, MD Medical Oncology · Bronx, NY
- Gabriel R. Tinoco Suarez, M.D. Medical Oncology · Columbus, OH
- Margaret Von-mehren, M.D. Medical Oncology · Philadelphia, PA
- John A. Charlson, M.D. Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic Jacksonville $831,220
- The American Oncologic Hospital DBA Hospital of the Fox Chase Cancer Center $733,500
- Northwestern Center for Clinical Research $148,153
- The Regents of the University of California $53,098
- Moffitt Cancer Center $51,919
- Memorial Sloankettering Cancer Center $30,549
- University of Iowa Hospital & Clinics, IA $22,456
- The American Ocologic Hospital DBA Hospital of the Fox Chase Cancer Center $16,978
- The Medical College of Wisconsin Inc $10,339
- Montefiore Medical Center, NY $9,195
- University of Miami $7,362
- Mayo Clinic Hospital, AZ $6,750
- Yale University $3,416
- The Ohio State University $3,034
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.